1. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers Grace Banik, Courtney B. Betts, Shannon M. Liudahl, Shamilene Sivagnanam, Rie Kawashima, Tiziana Cotechini, William Larson, Jeremy Goecks, Sara I. Pai, Daniel R. Clayburgh, Takahiro Tsujikawa and Lisa M. Coussens 2. Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment Giosuè Scognamiglio, Mariaelena Capone, Domenico Mallardo, Gerardo Botti, Paolo A. Ascierto and Gabriele Madonna 3. Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images Michael Surace, Lorenz Rognoni, Jaime Rodriguez-Canales and Keith E. Steele 4. Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ Angela Vasaturo and Jérôme Galon 5. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche Marcus Bauer, Christoforos Vaxevanis, Daniel Bethmann, Chiara Massa, Nikolaos Pazaitis, Claudia Wickenhauser and Barbara Seliger 6. Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry Ileana S. Mauldin, Natasha D. Sheybani, Samuel J. Young, Richard J. Price and Craig L. Slingluff 7. Tracing bone marrow-derived microglia in brain metastatic tumors Wei Du and Paula D. Bos 8. Monitoring abscopal responses to radiation in mice Maria Esperanza Rodriguez-Ruiz, Takahiro Yamazaki, Aitziber Buqué, Norma Bloy, Viviane A. O. Silva, Lena Stafford, Ai Sato and Lorenzo Galluzzi 9. Methods to assess anticancer immune responses in orthotopic bladder carcinomas Randy F. Sweis 10. Characterization of conventional dendritic cell populations in preclinical tumor models using flow cytometry Erik Wennerberg, Nils Rudqvist and Sheila Spada 11. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues Kathleen M. Kokolus, Natasa Obermajer and Pawel Kalinski 12. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption Praveen K. Bommareddy, Cole Peters and Howard L. Kaufman 13. Production and use of adeno-associated virus vectors as tools for cancer immunotherapy Myriam Fernandez-Sendin, Shirley Tenesaca, Marcos Vasquez, Fernando Aranda and Pedro Berraondo 14. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition João Manuel Santos, Riikka Havunen and Akseli Hemminki 15. Genetic modification of oncolytic viruses to enhance antitumor immunity Maria Eugenia Davola, Alyssa Vito, Jiarun Wei, Nader El-Sayes, Samuel Workenhe and Karen Louise Mossman 16. CRISPR technology for immuno-oncology applications Jianbin Wang, Vitaly Balan and Francesco Marincola 17. Neoantigen prediction from genomic and transcriptomic data Sebastiano Battaglia 18. Monitoring antigen cross-presentation with human dendritic cells purified from the blood Stephane Isnard, Etienne Hatton, Jean-Baptiste Guillerme and Anne Hosmalin
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome "La Sapienza. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.